Global Oncology Market

Oncology Market Size, Share, Growth Analysis, By Cancer Diagnostics & Treatment(Cancer Diagnostics {Tumor Biomarker Test, Imaging, Biopsy, Liquid Biopsy), By Cancer Type(Lung Cancer, Prostate Cancer, Colon & Rectal Cancer, Gastric Cancer), By End Use(Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Academia), By Region - Industry Forecast 2024-2031


Report ID: SQSG35J2013 | Region: Global | Published Date: October, 2024
Pages: 157 | Tables: 103 | Figures: 76

Oncology Market News

  • In July 2021, AstraZeneca announced that their medicine Imfinzi has been approved for the treatment of patients with non-small cell lung cancer by China's National Medical Products Administration.
  • In June 2021, Bayer AG has announced an agreement to buy Noria Therapeutics Inc. and PSMA Therapeutics Inc. Bayer will obtain exclusive rights to the company's experimental substance under this agreement. This acquisition will aid Bayer's cancer portfolio expansion.
  • In April 2021, Sanofi announced the acquisition of Tidal Therapeutics, a pre-clinical biotech firm developing an mRNA-based research platform. Sanofi will be able to use this new technology platform to expand their research capabilities in oncology, immunology, and other disease areas as a result of this acquisition.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Oncology Market size was valued at around USD 201.8 billion in 2022 and is expected to rise from USD 224.4 billion in 2023 to reach a value of USD 471.8 billion by 2031, at a CAGR of 11.2% over the forecast period (2024–2031).

The oncology market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies in order to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D in order to supply industries with the most efficient and cost-effective solutions. 'Roche Holding AG ', 'Novartis International AG ', 'Pfizer Inc. ', 'Bristol-Myers Squibb Company ', 'Merck & Co., Inc. ', 'AstraZeneca plc ', 'Johnson & Johnson (Janssen Pharmaceuticals) ', 'Eli Lilly and Company ', 'Amgen Inc. ', 'Sanofi S.A. ', 'Bayer AG ', 'Takeda Pharmaceutical Company ', 'AbbVie Inc. ', 'Gilead Sciences, Inc. ', 'Astellas Pharma Inc. ', 'Celgene Corporation (acquired by Bristol-Myers Squibb) ', 'Regeneron Pharmaceuticals, Inc. ', 'GlaxoSmithKline plc (GSK) ', 'Daiichi Sankyo Company, Limited ', 'Seagen Inc. '

The oncology market growth is attributed to the rising prevalence of cancer across the globe. Cancer has become the second greatest cause of death in the world, trailing only cardiovascular disease. This is caused by factors such as cigarette use, changing dietary patterns, and an extended post-reproductive lifespan. Cancer, for example, is a growing burden, with the number of new cancer cases expected to rise from 18.1 million in 2018 to 29.4 million by 2040, according to the World Health Organization (WHO). As a result, the rising prevalence of cancer is predicted to drive demand for worldwide oncology cancer medications during the forecast period. Furthermore, increased cancer awareness among the people is expected to benefit the global market in the approaching years.

The expansion of the oncology market is aided by the growing focus on R&D to increase adoption of advanced drug therapies. The goals of cancer treatment are to cure the disease, prolong survival, and improve quality of life. Immune cells are crucial in tumor growth. As a result, boosting immune responses to malignancies is an appealing therapeutic and preventative method. As a result, top market players are investing in immunotherapy research and development to treat various tumors. In March 2019, for example, FUJIFILM Corporation and the National Cancer Center Japan announced the start of a joint research effort for novel cancer immunotherapy employing a liposome formulation. Immunotherapy has a stronger market adoption due to its success in terms of efficient treatment, which results in better patient outcomes. As a result, this contributes to market growth.

In 2021, North America is expected to have the biggest share of the global oncology market. The region's dominance is due to the increased incidence and prevalence of cancer in the United States, as well as new product introductions in the region. According to the National Cancer Institute, roughly 1.8 million people in the United States will be diagnosed with cancer in 2020. Europe, after North America, is expected to account for the second-largest share of the global market. Because of the rising cancer burden, high-growth countries such as the United Kingdom, Germany, France, Italy, and Spain will contribute to the expansion of the European oncology market. Because of increased population awareness, the Asia Pacific oncology market is likely to grow at a quicker rate. The rising prevalence of cancer and rising healthcare costs will boost regional growth. Latin America, the Middle East, and Africa are projected to see sluggish development due to a lack of awareness and affordability of high-cost biologic medications.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Oncology Market

Report ID: SQSG35J2013

$5,300
BUY NOW GET FREE SAMPLE